Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.
Immunitas Therapeutics has raised $58.0M in total funding. The most recent round was Series B. The last funding was announced in August 2021.
Immunitas Therapeutics's investors include Longwood Fund, Evotec, Mirae Asset, Blood Cancer United, Inc., Ono Venture Investment.
Immunitas Therapeutics is headquartered in Cambridge, United States.
Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.
Immunitas Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunitas Therapeutics — Funding & Investors." VCBacked, August 18, 2021, https://www.vcbacked.co/company/immunitas-therapeutics. Accessed September 30, 2026.
VCBacked. (2021). Immunitas Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/immunitas-therapeutics
{{cite web |title=Immunitas Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/immunitas-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated